• First Scenesse Procedures in the United States Done Today April 29, 2020

    Resnik Skin Institute is proud to announce that the first 2 Scenesse procedures in the United States were performed today at our clinic in Miami, Florida. Scenesse®, made by Clinuvel, Inc., is the revolutionary new treatment for Erythropoietic Protoporphyria (EPP), a disease that keeps its sufferers in the dark. Until now.

    Read more

  • Virtual Visits during the COVID Crisis

    No matter how minor or serious a problem is, access to your doctor when you need it is a comforting thing during our COVID Crisis. Virtual Visits allow us to get together with you and interact in real-time. I believe in touch and talk and humor during our visits. Touch has been eliminated in this pandemic, but we can still talk and make jokes in this dark time, now via a screen.

    Read more

  • Scenesse now available for Erythropoietic Protoporphyria (EPP)

    Scenesse is a medicine that can give sufferers of Erythropoietic Protoporphyria (EPP) a new lease on life. The FDA approval of Scenesse for EPP in October 2019 was a watershed moment for US patients with this devastating disease. It has been a long time coming and it is now ready for use. The path to insurance approval is long and arduous but doable. Because it was just approved by the FDA, it will require a lot of flips and twists to get it to the patients who need it.

    Read more

  • HS, Covid-19 and Life

    In light of everything going on with COVID-19, the HS Foundation has teamed up with LearnSkin to provide guidance to HS physicians and patients about risks and management considerations in this challenging and unusual time.

    Read more

  • More News on Scenesse in Vitiligo

    Clinuvel just announced today that the FDA has agreed to discuss and implement the North American development program for SCENESSE (afamelanotide 16mg) for the pigment loss disorder vitiligo.

    Read more

FirstPrevious | Pages 1 [2] 3 4 5 6 7 of 10 | Next | Last

Love this Post? Spread the World